EN DE
STOCK COMPARISON

NexgenRX vs Veeva Systems Inc Class A: Fair Value & Quality

Both stocks run through our valuation models. Here is how NexgenRX (NXG) and Veeva Systems Inc Class A (VEEV) compare, as of Aug 10, 2026.

As of Aug 10, 2026, Fair Value Calculator sees NexgenRX as the less overvalued of the two: NexgenRX trades at C$0.60 versus a fair value of C$0.40 (-33%), while Veeva Systems Inc Class A trades at $230 versus $95.12 (-59%).
NexgenRX
NXG.V · CAD · Health Care
-33%
upside to fair value
overvalued
PriceC$0.60
Fair ValueC$0.40
Quality69/100
Veeva Systems Inc Class A
VEEV · USD · Health Care
-59%
upside to fair value
overvalued
Price$230
Fair Value$95.12
Quality72/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

NexgenRXVeeva Systems Inc Class A
Valuation
22.0×P/E (TTM)33.6×
1.22×P/S (TTM)9.31×
2.95×P/B4.28×
6.2×EV/EBITDA28.7×
6.53×PEG0.85×
3.5%Dividend yield
C$0.02Dividend per share
Profitability
11%Net margin28%
25%Operating margin31%
24%Return on equity14%
5%Return on assets7%
Growth
12%Revenue growth (YoY)16%
11.9%Avg. growth/yr (3Y)14.0%
10.2%Avg. growth/yr (5Y)16.9%
Balance & size
0.04×Debt / equity
$22MMarket cap$31B
healthyGrowth qualityhealthy

Veeva Systems Inc Class A leads: 5 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

NexgenRXof which business quality 67 · market factors 79 Veeva Systems Inc Class Aof which business quality 72 · market factors 48
ProfitabilityMargins and returns on capital today
48
57
Quality GrowthAre margins and returns improving?
44
65
CashflowEarnings quality: real cash, not paper profit
98
93
Fin. StrengthBalance sheet, leverage, solvency risk
54
91
InvestmentDisciplined investing over empire-building
79
33
Low VolatilityCalm price path (market factor)
49
55
MomentumPrice trend over the last 3–12 months (market factor)
87
52
52W MomentumDistance to the 52-week high (market factor)
100
31
Net IssuanceBuybacks instead of dilution
80
72

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

NexgenRX

DCF ModelsC$0.75
Earnings-BasedC$0.25
MultiplesC$0.44
Asset-BasedC$0.07
Growth DCFC$0.83
Economic ProfitC$0.23
Growth EarningsC$0.35

13 of 24 models see the stock below the current price.

Veeva Systems Inc Class A

DCF Models$214
Earnings-Based$142
Dividend Discount$0.41
Multiples$93.60
Asset-Based$29.76
Growth DCF$200
Economic Profit$57.47
Growth Earnings$185

21 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

NexgenRX
Bear C$0.30Fair Value C$0.40Bull C$0.50
C$0.60 = current price (white tick)
Veeva Systems Inc Class A
Bear $71.34Fair Value $95.12Bull $146
$230 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

NexgenRX · Health Care

Quality score69 · Top 25%
Fair value upside-33% · below median

Veeva Systems Inc Class A · Health Care

Quality score72 · Top 25%
Fair value upside-59% · below median

Bottom line

As of Aug 10, 2026, Fair Value Calculator sees NexgenRX as the less overvalued of the two: NexgenRX trades at C$0.60 versus a fair value of C$0.40 (-33%), while Veeva Systems Inc Class A trades at $230 versus $95.12 (-59%).

Veeva Systems Inc Class A has the higher quality score (72/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.